Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

Stopped early

Conditions studied: Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Melanoma, Metastatic Prostate Cancer

In brief

Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment. It, however, remains unclear if these new diagnostic technologies truly influence clinical and economic outcomes. This study will evaluate if patients treated according to the results of the NantHealth GPS Cancer test achieve optimal outcomes compared to patients whose treatment are discordant with GPS Cancer recommendations.

Key facts

Study ID

NCT03073473

Run by

Cota Inc.

People needed

40

Starts

2017-02-28

Expected to finish

2018-06-13

Last updated by the study team

2018-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pancreatic cancer patients ineligible for curative surgery at time of entry will be eligible for enrollment.
• Metastatic breast cancer at any time in their treatment history will be eligible for enrollment.
• Advanced stage (non-resectable/metastatic/incurable) lung cancer patients will be eligible for enrollment.
• Metastatic colon cancer patients not amenable to curative therapy will be eligible for enrollment.
• Metastatic non-resectable malignant melanoma patients will be eligible for enrollment.
• NantHealth GPS Cancer in Advanced Cancers
• Metastatic hormone refractory prostate cancer patients will be eligible for enrollment. Patients must have tumor tissue available prior to the initiation of the current line of treatment available for GPS Cancer testing.
• Metastatic bladder cancer
• Non-resectable metastatic Renal carcinoma
• Non-resectable metastatic Head and Neck cancer
• Metastatic Ovarian cancer
• Metastatic Cervical cancer
• Metastatic Sarcoma
• Patients must sign informed consent for this study.
• Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield. This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs.

You may not qualify if…

• Pregnancy.

Where it is running

• RCCA - Central Jersey Division — East Brunswick, New Jersey, United States
• RCCA - Freehold Division — Freehold, New Jersey, United States
• Hackensack Meridian Health System — Hackensack, New Jersey, United States
• RCCA - Hackettstown Division — Hackettstown, New Jersey, United States
• RCCA - Howell Division — Howell Township, New Jersey, United States
• RCCA - Little Silver Division — Little Silver, New Jersey, United States
• RCCA - Marmora Division — Marmora, New Jersey, United States
• RCCA - Mount Holly Division — Mount Holly, New Jersey, United States
• RCCA - Pompton Plains Division — Pompton Plains, New Jersey, United States
• RCCA - Sparta Division — Sparta, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.